The Role of Oxidative Stress in Blood-brain Barrier Disruption During Ischemic Stroke: Antioxidants in Clinical Trials

Overview

Journal Biochem Pharmacol

Specialties Biochemistry
Pharmacology

Date 2024 Apr 1

PMID 38561092

Authors

Jeffrey J Lochhead

Patrick T Ronaldson

Thomas P Davis

Affiliations

Soon will be listed here.

Abstract

Ischemic stroke is one of the leading causes of death and disability. Occlusion and reperfusion of cerebral blood vessels (i.e., ischemia/reperfusion (I/R) injury) generates reactive oxygen species (ROS) that contribute to brain cell death and dysfunction of the blood-brain barrier (BBB) via oxidative stress. BBB disruption influences the pathogenesis of ischemic stroke by contributing to cerebral edema, hemorrhagic transformation, and extravasation of circulating neurotoxic proteins. An improved understanding of mechanisms for ROS-associated alterations in BBB function during ischemia/reperfusion (I/R) injury can lead to improved treatment paradigms for ischemic stroke. Unfortunately, progress in developing ROS targeted therapeutics that are effective for stroke treatment has been slow. Here, we review how ROS are produced in response to I/R injury, their effects on BBB integrity (i.e., tight junction protein complexes, transporters), and the utilization of antioxidant treatments in ischemic stroke clinical trials. Overall, knowledge in this area provides a strong translational framework for discovery of novel drugs for stroke and/or improved strategies to mitigate I/R injury in stroke patients.

Citing Articles

Reactive Oxygen Species-Responsive Chitosan-Bilirubin Nanoparticles Loaded with Statin for Treatment of Cerebral Ischemia.

Raveena Nagareddy , Kim J, Kim J, Thomas R, Choi K, Jeong Y Biomater Res. 2024; 28:0097.

PMID: 39450150 PMC: 11499631. DOI: 10.34133/bmr.0097.

Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer's Disease: The Potential Role of a Novel Nano-Compound-The Transdermal Glutathione-Cyclodextrin Complex.

Yutani R, Venketaraman V, Sheren N Antioxidants (Basel). 2024; 13(9).

PMID: 39334765 PMC: 11429141. DOI: 10.3390/antiox13091106.

References

Fidalgo M, Ricardo Pires J, Viseu I, Magalhaes P, Gregorio H, Afreixo V . Edaravone for acute ischemic stroke - Systematic review with meta-analysis. Clin Neurol Neurosurg. 2022; 219:107299. DOI: 10.1016/j.clineuro.2022.107299. View

Yagi K, Kitazato K, Uno M, Tada Y, Kinouchi T, Shimada K . Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke. 2008; 40(2):626-31. DOI: 10.1161/STROKEAHA.108.520262. View

Cheng G, Zhao W, Xin Y, Huang G, Liu Y, Li Z . Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke. J Neurochem. 2021; 157(3):586-598. DOI: 10.1111/jnc.15308. View

Bauer M, Karch R, Zeitlinger M, Philippe C, Romermann K, Stanek J . Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. J Cereb Blood Flow Metab. 2015; 35(5):743-6. PMC: 4420865. DOI: 10.1038/jcbfm.2015.19. View

Hernandes M, Xu Q, Griendling K . Role of NADPH Oxidases in Blood-Brain Barrier Disruption and Ischemic Stroke. Antioxidants (Basel). 2022; 11(10). PMC: 9598888. DOI: 10.3390/antiox11101966. View

Nito C, Kamada H, Endo H, Niizuma K, Myer D, Chan P . Role of the p38 mitogen-activated protein kinase/cytosolic phospholipase A2 signaling pathway in blood-brain barrier disruption after focal cerebral ischemia and reperfusion. J Cereb Blood Flow Metab. 2008; 28(10):1686-96. PMC: 2562626. DOI: 10.1038/jcbfm.2008.60. View

Abo-Ramadan U, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E . Post-ischemic leakiness of the blood-brain barrier: a quantitative and systematic assessment by Patlak plots. Exp Neurol. 2009; 219(1):328-33. DOI: 10.1016/j.expneurol.2009.06.002. View

Dominguez C, Delgado P, Vilches A, Martin-Gallan P, Ribo M, Santamarina E . Oxidative stress after thrombolysis-induced reperfusion in human stroke. Stroke. 2010; 41(4):653-60. DOI: 10.1161/STROKEAHA.109.571935. View

Casas A, Kleikers P, Geuss E, Langhauser F, Adler T, Busch D . Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest. 2019; 129(4):1772-1778. PMC: 6436900. DOI: 10.1172/JCI124283. View

10.

Asahi M, Asahi K, Wang X, Lo E . Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2000; 20(3):452-7. DOI: 10.1097/00004647-200003000-00002. View

11.

Witt K, Mark K, Sandoval K, Davis T . Reoxygenation stress on blood-brain barrier paracellular permeability and edema in the rat. Microvasc Res. 2007; 75(1):91-6. PMC: 2243179. DOI: 10.1016/j.mvr.2007.06.004. View

12.

Maier C, Hsieh L, Crandall T, Narasimhan P, Chan P . Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann Neurol. 2006; 59(6):929-38. DOI: 10.1002/ana.20850. View

13.

Kahles T, Kohnen A, Heumueller S, Rappert A, Bechmann I, Liebner S . NADPH oxidase Nox1 contributes to ischemic injury in experimental stroke in mice. Neurobiol Dis. 2010; 40(1):185-92. DOI: 10.1016/j.nbd.2010.05.023. View

14.

Ray P, Huang B, Tsuji Y . Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012; 24(5):981-90. PMC: 3454471. DOI: 10.1016/j.cellsig.2012.01.008. View

15.

Bernardo-Castro S, Sousa J, Bras A, Cecilia C, Rodrigues B, Almendra L . Pathophysiology of Blood-Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery. Front Neurol. 2020; 11:594672. PMC: 7756029. DOI: 10.3389/fneur.2020.594672. View

16.

Lam T, Wise P, ODonnell M . Cerebral microvascular endothelial cell Na/H exchange: evidence for the presence of NHE1 and NHE2 isoforms and regulation by arginine vasopressin. Am J Physiol Cell Physiol. 2009; 297(2):C278-89. PMC: 2724093. DOI: 10.1152/ajpcell.00093.2009. View

17.

Shinohara Y, Saito I, Kobayashi S, Uchiyama S . Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis. 2009; 27(5):485-92. DOI: 10.1159/000210190. View

18.

KONTOS H . Oxygen radicals in cerebral ischemia: the 2001 Willis lecture. Stroke. 2001; 32(11):2712-6. DOI: 10.1161/hs1101.098653. View

19.

Zheng J, Chen X . Edaravone offers neuroprotection for acute diabetic stroke patients. Ir J Med Sci. 2015; 185(4):819-824. DOI: 10.1007/s11845-015-1371-9. View

20.

Maki T, Hayakawa K, Pham L, Xing C, Lo E, Arai K . Biphasic mechanisms of neurovascular unit injury and protection in CNS diseases. CNS Neurol Disord Drug Targets. 2013; 12(3):302-15. PMC: 3845030. DOI: 10.2174/1871527311312030004. View